Tag Archives: inclisiran

Introduction Ischaemic heart disease is the leading cause of death globally, responsible for 13% of all deaths in 2021.1 Acute coronary syndrome (ACS) represents a key opportunity for secondary prevention to reduce the risk of recurrent cardiovascular (CV) events.2 Lipid-lowering therapy (LLT) is central to this, with elevated levels of low-density lipoprotein cholesterol (LDL-C) being a key initiating factor in atherosclerosis:3 every 1 mmol/L reduction is associated with an approximate 22% decrease in the risk of major CV events.4 For patients with ACS, the National Institute for Health and Care Excellence (NICE) recommends:5,6 Early initi

Introduction Small-interfering RNA (siRNA)-based therapies offer a promising approach to cardiovascular disease (CVD) prevention. Inclisiran is a siRNA that reduces the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9), thereby increasing low-density lipoprotein (LDL)-receptor recycling and removal of LDL particles from the circulation. In phase 3 clinical trials,1 its effects are akin to anti-PCSK9 monoclonal antibodies, which have documented benefits in the prevention of CVD.2 Indeed, there is a well-established benefit of LDL-cholesterol (LDL-C) reduction regardless of mechanism.3 Inclisiran has some practical benefits co

Introduction Our previous study on the efficacy and tolerability of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibiting monoclonal antibodies (mAbs), such as alirocumab and evolocumab, in real-world clinical practice confirmed significant and sustained reductions in LDL-C levels. These findings were observed in high-risk, statin-intolerant patients and others with known cardiovascular (CV) disease risks.1 Notably, our real-world results aligned with outcomes reported in pivotal trials, such as the ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) and FOURIE

What’s new in transplantation Are kidney donors worse off? The meeting was opened by Dr Anna Price (Queen Elizabeth University Hospital, Birmingham) who addressed the long-term cardiovascular effects of unilateral nephrectomy in living kidney donors.1 Previous studies have shown a significant prevalence of cardiovascular morbidity and mortality in patients with chronic kidney disease (CKD),2,3 but the effects of reduced renal function in living kidney donors has been unexplored until now. A recent study by Price et al. demonstrated that living kidney donors had a reduction in estimated glomerular filtration rate (eGFR) from 95 to 67 ml/min

Data presented at the recent American Heart Association Scientific Sessions 2020, showed pooled results from three ORION phase III trials in more than 3,600 patients with atherosclerotic cardiovascular disease (or heterozygous familial hypercholesterolemia (HeFH), who were given inclisiran at months 1, 3 and then every 6 months up to month 17. Results of the first analysis showed LDL-C reductions of approximately 51% from baseline for both women and men at 17 months. A second analysis demonstrated treatment with inclisiran lowered LDL-C similarly by approximately 51% across three age groups (<65, ≥65 to <75, and ≥75 years old). In b